| abstract |
The present invention provides a salt of the compound of formula (I), said salt being a phosphate in a crystalline form or an amorphous form, or an oxalate in a crystalline form or an amorphous form. In particular, phosphate crystal form B of the present invention has high crystallinity, low hygroscopicity and good stability, and phosphate crystal form B has good oral bioavailability and good tolerance for long-term administration, is not easy to induce hypoglycemia, and has good serum DPPIV inhibitory effect at the same time. |